2022
DOI: 10.3390/ijms23158161
|View full text |Cite
|
Sign up to set email alerts
|

The Pt(S-pr-thiosal)2 and BCL1 Leukemia Lymphoma: Antitumor Activity In Vitro and In Vivo

Abstract: B cell malignancies are, despite the development of targeted therapy in a certain percentage of the patients still a chronic disease with relapses, requiring multiple lines of therapy. Regimens that include platinum-based drugs provide high response rates in different B cell lymphomas, high-risk chronic lymphocytic leukemia (CLL), and devastating complication of CLL, Richter’s syndrome. The aim of this study was to explore the potential antitumor activity of previously synthetized platinum(IV) complex with alk… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 105 publications
0
1
0
Order By: Relevance
“…It reduced in vitro the viability of murine B-cell leukaemia lymphoma cells, BCL1, but also decreased the growth of metastases in the leukaemia lymphoma model in BALB/c mice. Moreover, PtCl 2 ( S -pr-thiosal) 2 induced apoptosis and cell cycle disturbance, resulting in cell cycle arrest in the G1 phase [ 17 ].…”
mentioning
confidence: 99%
“…It reduced in vitro the viability of murine B-cell leukaemia lymphoma cells, BCL1, but also decreased the growth of metastases in the leukaemia lymphoma model in BALB/c mice. Moreover, PtCl 2 ( S -pr-thiosal) 2 induced apoptosis and cell cycle disturbance, resulting in cell cycle arrest in the G1 phase [ 17 ].…”
mentioning
confidence: 99%